Explore the latest in leukemias, including recent advances in management of acute and chronic lymphocytic and myeloid leukemias.
This nonrandomized clinical trial evaluates molecular recurrence and patient-reported outcomes after tyrosine kinase inhibitor discontinuation in US patients with chronic myeloid leukemia.
A 50-year-old woman with recently diagnosed acute myeloid leukemia has a 3-week history of a pruritic and generalized cutaneous eruption. What is your diagnosis?
This meta-analysis examines the use of measurable residual disease as an end point in studies to assess survival outcomes in patients with acute myeloid leukemia.
This case report describes acute macular neuroretinopathy in a young woman with acute myeloid leukemia who was treated with the FLT3 inhibitor gilteritinib.
This cohort study identifies trends in tyrosine kinase inhibitor use in patients with chronic myelogenous leukemia and the association those treatment choices have with health care costs.
This systematic review investigates whether published data support the safety and effectiveness of microtransplantation of hematopoietic cells in persons with acute myeloid leukemia and myelodysplastic syndrome.
This randomized clinical trial examines whether a multicomponent intervention results in a higher proportion of pediatric patients with acute lymphoblastic leukemia maintaining mercaptopurine adherence rates of 95% or higher compared with education alone.
This case report describes a 63-year-old man with acute myeloid leukemia who presented with a red, dome-shaped papule under the right lower eyelid.
This cohort study identifies and validates independent transplant- and host-associated risk factors for keratinocyte carcinoma among patients undergoing allogeneic hematopoietic cell transplant.
In this narrative medicine essay, Donald M. Berwick shares the story of his patient Isaiah with the 2012 Harvard Medical School graduating class as an example of a patient who deserved the treatment that cured him of leukemia but whose life was lost to poverty and exhorts them to regard health care as human right that must be preserved in the clinic and in public.
In this narrative medicine essay, a clinical educator uses her experiences enduring the aftermath of treatment for acute myeloid leukemia to reflect on the difference between physician-teachers and patients’ experience of illness and to locate meaning in what she can offer her colleagues and trainees despite persistent disability.
This cohort study compares health care expenditures of patients with chronic myeloid leukemia for first- and second-generation tyrosine kinase inhibitors before and after the transition of imatinib to generic status.
This case report presents the response to experimental drug gilteritinib hemifumarate in a patient with ophthalmological complications of relapsed acute myeloid leukemia with FMS-like tyrosine kinase 3 (FLT3) gene mutation.
A 13-year-old with a medullar and meningeal relapse of T-cell acute lymphocytic leukemia presents with decreased visual acuity in both eyes from a rare, leukemia-associated cause.
This phase 3 randomized clinical trial assesses whether dasatinib given at 80 mg/m2 is more effective than imatinib mesylate at 300 mg/m2 to improve event-free survival in children with Philadelphia chromosome–positive acute lymphoblastic leukemia.
This cost-utility analysis assesses the value of tisagenlecleucel compared with current standard care for tisagenlecleucel-eligible pediatric patients with acute lymphoblastic leukemia.
This cohort study compares idelalisib treatment outcomes in the clinical setting among Medicare beneficiaries with outcomes in clinical trial data.
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: